Systemic Bio

Founded with a mission to revolutionize drug discovery and development, Systemic Bio leverages cutting-edge 3D bioprinting technology to create organs-on-chips. These bioprinted models mimic human organ functions, providing a more accurate and efficient platform for preclinical drug testing. Their proprietary platform, built with advanced 3D Systems technology, offers at least 10 times greater build volume and up to 10 times higher resolution than existing commercial technologies, positioning Systemic Bio at the forefront of biomedical innovation.

Systemic Bio boasts a team of leading bioengineering experts dedicated to pushing the boundaries of preclinical drug testing. The company has garnered attention for its state-of-the-art laboratory and significant technological advancements. Notable investors and affiliations include key figures in the biotech and pharmaceutical industries, further validating its impact. Systemic Bio's innovative approach has the potential to significantly reduce the time and cost associated with drug development, making it a pivotal player in the healthcare sector.